Floatz logo

Igc Ad1

Agitation,Psychomotor

IGC Pharma, LLCPhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
95/ 100

Competitive context

3 Active assets in the Agitation,Psychomotor cohort.

Asset / SponsorPhaseRating
Bxcl501
Centre Integre Universitaire de Sante et Services Sociaux du Nord de l'ile de Montreal
Phase 4A
Axs-05
Axsome Therapeutics, Inc.
Phase 3BB
Wellbutrin
Axsome Therapeutics, Inc.
Phase 2/3B
Low THC
Mclean Hospital
Early Phase 1C
Marijuana
M. H MediCane Ltd.
N/AD
Loxapine
Wake Forest University Health Sciences
D

Same molecule, other indications

Igc Ad1 is also rated in:

disruptive behavior disorderDormant
CCC
Indicative ·
53 / 100
View asset →
Alzheimer diseaseDormant
CCC
Indicative ·
52 / 100
View asset →
Alzheimer diseaseDormant
NR
Indicative ·
/ 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →